Efficacy and safety assessment of propranolol tablets vs. oral solution for infantile hemangioma: a retrospective study in China

BackgroundPropranolol for infantile hemangiomas (IHs) is effective and relatively safe. However, propranolol has different formulations and there is no consensus on the optimal formulation for IHs. The propranolol oral solution was not used in China until 2022.ObjectiveTo evaluate the efficacy and s...

Full description

Saved in:
Bibliographic Details
Main Authors: Wenting Chen, Hua Qian, Qi Sun, Shan Zhang, Lei Zhu, Yafen Wu, Yingying Qian, Bingbing Wang, Wei Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Pediatrics
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2025.1542348/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832542345323610112
author Wenting Chen
Hua Qian
Qi Sun
Shan Zhang
Lei Zhu
Yafen Wu
Yingying Qian
Bingbing Wang
Wei Li
author_facet Wenting Chen
Hua Qian
Qi Sun
Shan Zhang
Lei Zhu
Yafen Wu
Yingying Qian
Bingbing Wang
Wei Li
author_sort Wenting Chen
collection DOAJ
description BackgroundPropranolol for infantile hemangiomas (IHs) is effective and relatively safe. However, propranolol has different formulations and there is no consensus on the optimal formulation for IHs. The propranolol oral solution was not used in China until 2022.ObjectiveTo evaluate the efficacy and safety of propranolol tablets and an oral solution in infants with high-risk IH.MethodsA retrospective cohort study was conducted involving 234 consecutive patients with a clinical diagnosis of high-risk IH who were treated with propranolol between August 2018 and February 2023 (propranolol tablets, 168 patients; propranolol oral solution, 66 patients). All patients were assessed in the hospital at the initiation of treatment and in the outpatient setting during treatment. The Hemangioma Activity and Severity Index was used to monitor the clinical activity of the hemangioma after propranolol treatment.ResultsBased on the Hemangioma Activity and Severity Index, 66.52% and 69.15% improvement occurred in the propranolol tablet and oral solution groups, respectively. 23.21% of patients in the propranolol tablet group and 42.42% in the oral solution group achieved >75% score improvement (X2 = 8.557; P = 0.003). Adverse reactions occurred in 34 (20.24%) and 11 patients (16.67%) in the propranolol tablet and oral solution groups, respectively. The most common adverse reaction in the propranolol tablet group was liver function abnormalities due to mild elevation of liver enzymes (X2 = 4.09; P = 0.045).ConclusionBoth propranolol tablets and oral solution had positive efficacy in patients with high-risk IHs, but more patients in the propranolol oral solution group achieve >75% score improvement compared to the propranolol tablet group. No life-threatening adverse reactions occurred in either group but liver function abnormalities were more likely to occur in patients treated with propranolol tablets.
format Article
id doaj-art-f07ab50074784dd3ab54b24be95397af
institution Kabale University
issn 2296-2360
language English
publishDate 2025-02-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pediatrics
spelling doaj-art-f07ab50074784dd3ab54b24be95397af2025-02-04T06:31:45ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602025-02-011310.3389/fped.2025.15423481542348Efficacy and safety assessment of propranolol tablets vs. oral solution for infantile hemangioma: a retrospective study in ChinaWenting ChenHua QianQi SunShan ZhangLei ZhuYafen WuYingying QianBingbing WangWei LiBackgroundPropranolol for infantile hemangiomas (IHs) is effective and relatively safe. However, propranolol has different formulations and there is no consensus on the optimal formulation for IHs. The propranolol oral solution was not used in China until 2022.ObjectiveTo evaluate the efficacy and safety of propranolol tablets and an oral solution in infants with high-risk IH.MethodsA retrospective cohort study was conducted involving 234 consecutive patients with a clinical diagnosis of high-risk IH who were treated with propranolol between August 2018 and February 2023 (propranolol tablets, 168 patients; propranolol oral solution, 66 patients). All patients were assessed in the hospital at the initiation of treatment and in the outpatient setting during treatment. The Hemangioma Activity and Severity Index was used to monitor the clinical activity of the hemangioma after propranolol treatment.ResultsBased on the Hemangioma Activity and Severity Index, 66.52% and 69.15% improvement occurred in the propranolol tablet and oral solution groups, respectively. 23.21% of patients in the propranolol tablet group and 42.42% in the oral solution group achieved >75% score improvement (X2 = 8.557; P = 0.003). Adverse reactions occurred in 34 (20.24%) and 11 patients (16.67%) in the propranolol tablet and oral solution groups, respectively. The most common adverse reaction in the propranolol tablet group was liver function abnormalities due to mild elevation of liver enzymes (X2 = 4.09; P = 0.045).ConclusionBoth propranolol tablets and oral solution had positive efficacy in patients with high-risk IHs, but more patients in the propranolol oral solution group achieve >75% score improvement compared to the propranolol tablet group. No life-threatening adverse reactions occurred in either group but liver function abnormalities were more likely to occur in patients treated with propranolol tablets.https://www.frontiersin.org/articles/10.3389/fped.2025.1542348/fullpropranolol hydrochloride oral solutionpropranolol hydrochloride tabletsinfantile hemangiomasafetyefficacy
spellingShingle Wenting Chen
Hua Qian
Qi Sun
Shan Zhang
Lei Zhu
Yafen Wu
Yingying Qian
Bingbing Wang
Wei Li
Efficacy and safety assessment of propranolol tablets vs. oral solution for infantile hemangioma: a retrospective study in China
Frontiers in Pediatrics
propranolol hydrochloride oral solution
propranolol hydrochloride tablets
infantile hemangioma
safety
efficacy
title Efficacy and safety assessment of propranolol tablets vs. oral solution for infantile hemangioma: a retrospective study in China
title_full Efficacy and safety assessment of propranolol tablets vs. oral solution for infantile hemangioma: a retrospective study in China
title_fullStr Efficacy and safety assessment of propranolol tablets vs. oral solution for infantile hemangioma: a retrospective study in China
title_full_unstemmed Efficacy and safety assessment of propranolol tablets vs. oral solution for infantile hemangioma: a retrospective study in China
title_short Efficacy and safety assessment of propranolol tablets vs. oral solution for infantile hemangioma: a retrospective study in China
title_sort efficacy and safety assessment of propranolol tablets vs oral solution for infantile hemangioma a retrospective study in china
topic propranolol hydrochloride oral solution
propranolol hydrochloride tablets
infantile hemangioma
safety
efficacy
url https://www.frontiersin.org/articles/10.3389/fped.2025.1542348/full
work_keys_str_mv AT wentingchen efficacyandsafetyassessmentofpropranololtabletsvsoralsolutionforinfantilehemangiomaaretrospectivestudyinchina
AT huaqian efficacyandsafetyassessmentofpropranololtabletsvsoralsolutionforinfantilehemangiomaaretrospectivestudyinchina
AT qisun efficacyandsafetyassessmentofpropranololtabletsvsoralsolutionforinfantilehemangiomaaretrospectivestudyinchina
AT shanzhang efficacyandsafetyassessmentofpropranololtabletsvsoralsolutionforinfantilehemangiomaaretrospectivestudyinchina
AT leizhu efficacyandsafetyassessmentofpropranololtabletsvsoralsolutionforinfantilehemangiomaaretrospectivestudyinchina
AT yafenwu efficacyandsafetyassessmentofpropranololtabletsvsoralsolutionforinfantilehemangiomaaretrospectivestudyinchina
AT yingyingqian efficacyandsafetyassessmentofpropranololtabletsvsoralsolutionforinfantilehemangiomaaretrospectivestudyinchina
AT bingbingwang efficacyandsafetyassessmentofpropranololtabletsvsoralsolutionforinfantilehemangiomaaretrospectivestudyinchina
AT weili efficacyandsafetyassessmentofpropranololtabletsvsoralsolutionforinfantilehemangiomaaretrospectivestudyinchina